Quantcast
Last updated on April 20, 2014 at 8:28 EDT

Latest Iron overload Stories

2014-01-08 20:21:27

- Patient safety and well-being are highest priority at Novartis Pharmaceuticals Corporation (NPC) EAST HANOVER, N.J., Jan. 8, 2014 /PRNewswire/ -- Patient safety and well-being are the highest priority at Novartis Pharmaceuticals Corporation (NPC). NPC is dedicated to improving patient health and supports patient medication adherence programs integral to this goal. These include outreach by pharmacies aimed at helping patients appropriately take their medicines as prescribed...

2013-09-10 14:24:24

Treatment for sickle cell disease has largely focused on managing pain and acute complications, but current research, including several projects at Texas Children’s Hematology Center, is now aimed at developing more efficient and progressive forms of treatment that could potentially benefit patients around the world. "Traditionally, treatment for sickle cell disease has been palliative, and there have not been a lot of options to prevent long term complications," said Dr. Alex George,...

2013-07-09 23:28:37

Resonance Health is pleased to announce the peer reviewed publication of a significant validation study for FerriScan R2-MRI. (PRWEB) July 09, 2013 FerriScan R2-MRI has gained international acknowledgement as the gold standard for non-invasive MRI measurement of liver iron concentration. This is now further substantiated by the publication of the paper demonstrating that the technology can be used in different MRI centres on different makes and models of scanners with no impact on the...

2013-02-07 08:28:27

HEIDELBERG, Germany, Feb. 7, 2013 /PRNewswire/ -- Apogenix GmbH, a clinical stage biopharmaceutical company developing novel protein therapeutics for the treatment of cancer and inflammatory diseases, announced today that its lead product, Apocept(TM) (APG101), has been granted orphan drug designation from the US Food and Drug Administration (FDA) for the treatment of Myelodysplastic syndromes (MDS). MDS are clonal hematopoietic stem cell disorders characterized by ineffective hematopoiesis...

2013-01-23 16:24:31

EAST HANOVER, N.J., January 23, 2013 /PRNewswire/ -- Novartis announced today that the US Food and Drug Administration (FDA) has approved Exjade(®) (deferasirox) for the treatment of chronic iron overload in patients 10 years of age and older with non-transfusion-dependent thalassemia (NTDT) syndromes and with a liver iron concentration of at least 5 mg of iron per gram dry weight and a serum ferritin measurement greater than 300 micrograms per liter. Exjade is the first treatment...

2012-06-14 22:20:43

AMSTERDAM, June 15, 2012 /PRNewswire/ -- "There is a large potential opportunity for saving lives by early identification of cardiac iron loading in Thalassemia patients", declares Professor John-Paul Carpenter of the Royal Brompton CMR Unit in London at the 17th Congress of the European Hematology Association in Amsterdam. Thalassemia major (TM) is a substantial health issue, with over 25,000 new transfusion-dependent children identified each year around the world. In...

2012-03-15 06:00:00

DUBLIN, March 15, 2012 /PRNewswire/ -- Shire plc (LSE: SHP, NASDAQ: SHPGY), the global specialty biopharmaceutical company, announces that it has signed an agreement to acquire FerroKin BioSciences, Inc., for an upfront payment of $100 million, payable in cash at closing, plus potential post-closing milestone payments of up to $225 million, depending upon the achievement of certain clinical development, regulatory and net sales targets. - A strategic step in...

2011-12-13 10:30:00

EAST HANOVER, N.J., Dec. 13, 2011 /PRNewswire/ -- Results from THALASSA, the first pivotal placebo-controlled study examining the benefit of iron chelation with Exjade(®) (deferasirox) in patients with non-transfusion-dependent thalassemia (NTDT), show that Exjade can significantly reduce iron overload. These data were presented today at the 53rd Annual Meeting of the American Society of Hematology in San Diego. THALASSA investigated whether patients with...

2011-11-01 21:11:53

Multiple organs, including the liver and the heart, become damaged if an individual has an excessive amount of iron in their body. Treatments for iron overload are arduous and/or have severe side effects. A team of researchers led by Elizabeta Nemeth, at the University of California, Los Angeles, has now generated data in mice that suggest that they have designed a promising new approach to reducing iron overload. Iron overload is a hallmark of the genetic disease hereditary...

2011-11-01 21:09:49

Iron overload is a common condition affecting millions of people worldwide. Excess iron in the body is toxic, and deposits can cause damage to the liver, heart and other organs. Current treatments, researchers say, are not ideal and have significant side effects. Iron in the body is regulated by a hormone called hepcidin, and a deficiency in this hormone can cause the iron overload seen in genetic disorders like hereditary hemochromatosis and Cooley's anemia. In the hopes of finding a...